Indication

Enzyme replacement therapy for the treatment of non-neurological manifestations in patients with mild to moderate alpha-mannosidosis.

Medicine details

Medicine name:
velmanase alfa (Lamzede)
SMC ID:
SMC2466
Pharmaceutical company
Chiesi Limited
BNF chapter
Nutrition and blood
Submission type
Ultra-orphan initial assessment
Publication due date:
12 September 2022
SMC meeting date:
02 August 2022
Patient group submission deadline:
04 July 2022